You are here: Industry Insights > ,

News List

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
Buyers and Sellers in the Weight Loss M&A Market：Without Buying and Selling, There's No Reshuffle Krebs Qin
December 20, 2024
The development of weight-loss drugs is currently one of the hottest topics in the pharmaceutical industry.
Universal CAR-T, Transaction +1 xiaobin
December 20, 2024
CAR-T therapy (chimeric antigen receptor t-cell immunotherapy) has been a favorite of the innovative drug market in recent years.
20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
December 13, 2024
Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.
The Multifaceted Benefits of Guaraná: Energy, Cognition, and Beyond David Orchard-Webb
December 04, 2024
Guaraná (Paullinia cupana) is a climbing plant endemic to the Amazon region, namely Brazil. This article looks at Guaraná's medicinal potential, traditional usage, and rising significance in modern health applications.
Innovative Strategies to Accelerate Drug R&D, and Regulatory Approvals Saher Haider
October 15, 2024
Global health crises, with the COVID-19 pandemic being the most predominant one, revealed the importance and the stark inefficiencies of traditional drug development pathways.
Ulinastatin in Japan, China, and India David Orchard-Webb
October 09, 2024
Ulinastatin, a naturally occurring protease modulator generated from human urine, has been used for decades to treat inflammatory disorders like sepsis, acute pancreatitis, and organ failure.
Professor James Rothman, Nobel Laureate, to Join the Board of Noscendo GmbH Biotech Newswire
August 21, 2024
Noscendo GmbH announced that Professor James Rothman has agreed to serve on its board as an independent director.
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024
Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.